OVERVIEW

Case Challenge: Incorporate Real-World Evidence (RWE) in the Management of Hormone Receptor-Positive Metastatic Breast Cancer (MBC) is organized by CME Outfitters, LLC.

Premiere Date: Monday, April 27, 2020
Credit Expiration Date: Tuesday, April 27, 2021

This activity offers CE credit for:
• Physicians (CME)
• Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Information:
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Bethesda, Maryland, USA. Please retain your certificate as proof of completion.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Statement of Need:
The use of real-world data (RWD) to generate real-world evidence (RWE) that reflects the complexity of usual treatment patterns of oncology care and clinical outcomes, and represents a broader spectrum of patients, can provide treatment benefit estimates outside the well-defined framework of trial settings. The potential for RWE is particularly significant in the oncology setting, where combination therapy offers great benefits for patients. Cyclin-dependent kinase (CDK) 4 and 6 inhibitors in combination with endocrine therapy (ET) have emerged as a standard-of-care treatment for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC), and RWE, when effectively deployed, can help determine treatment effects in the real world.

In this CME Outfitters BriefCase, expert faculty discuss the challenges and nuances of a case scenario as well as practical strategies for incorporating RWE into daily clinical practice in MBC.

Learning Objectives:
At the end of this CE activity, participants should be able to:
• Assess evidence on real-world, clinical experience for CDK 4/6 inhibitors in MBC.
• Integrate RWE into daily practice and decision-making in the MBC setting.